News | March 13, 2024
Evonik establishes a new research institute dedicated to skin sciences
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
An accomplished R&D leader and champion of the application of AI to drug discovery
This product has sales of about US$ 20 million in Europe
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
The agreement grants Brinter the distribution rights of GrowInk bioinks in many countries
Receives registration of Valganciclovir powder for oral solution in Germany
Subscribe To Our Newsletter & Stay Updated
